Bristol-Myers Squibb Q3 2025 Form 10-Q Report

These two sources are official financial filings from Bristol Myers Squibb (BMY), dated October 30, 2025, providing a comprehensive overview of the company’s third quarter and year-to-date results for 2025. The documents detail strong total revenues of $12.222 billion for the quarter, driven by an 18% increase in Growth Portfolio revenues, despite significant generic erosion affecting the Legacy Portfolio products like Revlimid and Sprycel. Furthermore, the filings outline a strategic focus on pipeline acceleration and business development, including recent acquisitions like Orbital Therapeutics and licensing agreements for new therapies. Finally, the sources provide extensive tables of GAAP and non-GAAP financial data, updates on key regulatory approvals, and disclosures regarding ongoing litigation and the impact of governmental pricing actions like the Inflation Reduction Act (IRA) on future operations.

There are no comments yet.

Please log in to write the first comment.